These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
529 related items for PubMed ID: 12884068
1. Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis. Colombo AL, Perfect J, DiNubile M, Bartizal K, Motyl M, Hicks P, Lupinacci R, Sable C, Kartsonis N. Eur J Clin Microbiol Infect Dis; 2003 Aug; 22(8):470-4. PubMed ID: 12884068 [Abstract] [Full Text] [Related]
2. Invasive candidiasis in cancer patients: observations from a randomized clinical trial. DiNubile MJ, Hille D, Sable CA, Kartsonis NA. J Infect; 2005 Jun; 50(5):443-9. PubMed ID: 15907554 [Abstract] [Full Text] [Related]
3. Comparison of caspofungin and amphotericin B for invasive candidiasis. Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J, Lupinacci R, Sable C, Kartsonis N, Perfect J, Caspofungin Invasive Candidiasis Study Group. N Engl J Med; 2002 Dec 19; 347(25):2020-9. PubMed ID: 12490683 [Abstract] [Full Text] [Related]
5. Caspofungin therapy of neonates with invasive candidiasis. Odio CM, Araya R, Pinto LE, Castro CE, Vasquez S, Alfaro B, Sàenz A, Herrera ML, Walsh TJ. Pediatr Infect Dis J; 2004 Dec 19; 23(12):1093-7. PubMed ID: 15626944 [Abstract] [Full Text] [Related]
6. Efficacy of micafungin in invasive candidiasis caused by common Candida species with special emphasis on non-albicans Candida species. Cornely OA, Vazquez J, De Waele J, Betts R, Rotstein C, Nucci M, Pappas PG, Ullmann AJ. Mycoses; 2014 Feb 19; 57(2):79-89. PubMed ID: 23786573 [Abstract] [Full Text] [Related]
7. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). Leroy O, Gangneux JP, Montravers P, Mira JP, Gouin F, Sollet JP, Carlet J, Reynes J, Rosenheim M, Regnier B, Lortholary O, AmarCand Study Group. Crit Care Med; 2009 May 19; 37(5):1612-8. PubMed ID: 19325476 [Abstract] [Full Text] [Related]
8. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Pappas PG, Rotstein CM, Betts RF, Nucci M, Talwar D, De Waele JJ, Vazquez JA, Dupont BF, Horn DL, Ostrosky-Zeichner L, Reboli AC, Suh B, Digumarti R, Wu C, Kovanda LL, Arnold LJ, Buell DN. Clin Infect Dis; 2007 Oct 01; 45(7):883-93. PubMed ID: 17806055 [Abstract] [Full Text] [Related]
9. Caspofungin use in patients with invasive candidiasis caused by common non-albicans Candida species: review of the caspofungin database. Colombo AL, Ngai AL, Bourque M, Bradshaw SK, Strohmaier KM, Taylor AF, Lupinacci RJ, Kartsonis NA. Antimicrob Agents Chemother; 2010 May 01; 54(5):1864-71. PubMed ID: 20231388 [Abstract] [Full Text] [Related]
10. High-dose liposomal amphotericin B in the therapy of systemic candidiasis in neonates. Juster-Reicher A, Flidel-Rimon O, Amitay M, Even-Tov S, Shinwell E, Leibovitz E. Eur J Clin Microbiol Infect Dis; 2003 Oct 01; 22(10):603-7. PubMed ID: 13680398 [Abstract] [Full Text] [Related]
11. Invasive candidiasis treated in the intensive care unit: observations from a randomized clinical trial. DiNubile MJ, Lupinacci RJ, Strohmaier KM, Sable CA, Kartsonis NA. J Crit Care; 2007 Sep 01; 22(3):237-44. PubMed ID: 17869975 [Abstract] [Full Text] [Related]
13. Caspofungin: a review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis. Keating G, Figgitt D. Drugs; 2003 Sep 01; 63(20):2235-63. PubMed ID: 14498760 [Abstract] [Full Text] [Related]
14. In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance. Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ. J Clin Microbiol; 2006 Mar 01; 44(3):760-3. PubMed ID: 16517851 [Abstract] [Full Text] [Related]
15. Caspofungin for invasive candidiasis at a tertiary care medical center. Zaas AK, Dodds Ashley ES, Alexander BD, Johnson MD, Perfect JR. Am J Med; 2006 Nov 01; 119(11):993.e1-6. PubMed ID: 17071169 [Abstract] [Full Text] [Related]
16. Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome. Kartsonis N, Killar J, Mixson L, Hoe CM, Sable C, Bartizal K, Motyl M. Antimicrob Agents Chemother; 2005 Sep 01; 49(9):3616-23. PubMed ID: 16127030 [Abstract] [Full Text] [Related]
17. Successful treatment of Candida krusei fungemia with amphotericin B and caspofungin. Olver WJ, Scott F, Shankland GS. Med Mycol; 2006 Nov 01; 44(7):655-7. PubMed ID: 17071561 [Abstract] [Full Text] [Related]
18. [Multicenter study of fungemia due to yeasts in Argentina]. Rodero L, Davel G, Soria M, Vivot W, Córdoba S, Canteros CE, Saporiti A, EMIFN. Rev Argent Microbiol; 2005 Nov 01; 37(4):189-95. PubMed ID: 16502638 [Abstract] [Full Text] [Related]
19. Antifungal resistance: the clinical front. Perfect JR. Oncology (Williston Park); 2004 Dec 01; 18(14 Suppl 13):15-22. PubMed ID: 15682590 [Abstract] [Full Text] [Related]
20. Successful treatment of Candida krusei infection with caspofungin acetate: a new antifungal agent. McGee WT, Tereso GJ. Crit Care Med; 2003 May 01; 31(5):1577-8. PubMed ID: 12771636 [Abstract] [Full Text] [Related] Page: [Next] [New Search]